Urofollitropin

Drug Overview

Urofollitropin is a highly specialized medication within the Gynecology category. It belongs to the Purified FSH (Follicle Stimulating Hormone) drug class. For women struggling to conceive, this medication is a vital tool in fertility treatments.

As a powerful Biologic and Hormone Modulator, urofollitropin is a highly purified preparation of naturally occurring hormones that directly stimulate the ovaries to produce healthy, mature eggs. It is a cornerstone medication used in both basic ovulation induction and advanced reproductive technologies like In Vitro Fertilization (IVF).

• Generic Name / Active Ingredient: Urofollitropin (Highly Purified Follicle Stimulating Hormone)
• US / International Brand Names: Bravelle (historic US brand), Fostimon, Alterpur
• Route of Administration: Subcutaneous (SC) injection into the fatty tissue, or Intramuscular (IM) injection.
• FDA Approval Status: Fully FDA-Approved

What Is It and How Does It Work? (Mechanism of Action)

Urofollitropin is a highly purified form of human follicle-stimulating hormone (FSH) extracted from the urine of postmenopausal women. It acts as a primary Hormone Modulator for the female reproductive system.

To understand its mechanism, we must look at the hypothalamic-pituitary-ovarian (HPO) axis. In a natural menstrual cycle, your brain releases a small amount of FSH to stimulate the growth of a single ovarian follicle (the fluid-filled sac containing an egg). Urofollitropin works by providing a concentrated, direct supply of this exact hormone to the ovaries:

• Receptor Agonism: Urofollitropin binds directly to the FSH receptors located on the granulosa cells (the cells surrounding the developing egg) inside the ovary.
• Follicular Growth and Maturation: By continuously activating these receptors, the drug bypasses the brain’s natural limits. It prompts the ovary to grow and mature either one dominant follicle (in basic treatments) or multiple follicles simultaneously (in IVF).
• Hormonal Production: As the follicles grow under the stimulation of urofollitropin, the cells begin to produce estrogen (estradiol). The rising estrogen levels help thicken the uterine lining, preparing it for the implantation of a fertilized egg.

FDA-Approved Clinical Indications

Urofollitropin is specifically designed to treat female infertility by overriding the body’s natural follicular selection process.

• Primary Gynecological/Obstetric Indications:
  • Ovulation Induction (OI): Triggering ovulation in women who do not ovulate naturally (anovulation), often used for women who have already tried other medications like clomiphene or letrozole without success.
  • Multifollicular Development for ART: Stimulating the development of multiple eggs for Assisted Reproductive Technologies (ART), such as In Vitro Fertilization (IVF) or Intracytoplasmic Sperm Injection (ICSI).
• Off-Label / Endocrinological Indications:
  • Male Infertility (Hypogonadotropic Hypogonadism): Used off-label in men alongside hCG to stimulate the testes to produce sperm (spermatogenesis).
  • Empiric Treatment for Unexplained Infertility: Used in conjunction with Intrauterine Insemination (IUI) to increase the number of targets (eggs) available for fertilization in couples with unexplained infertility.

Dosage and Administration Protocols

Urofollitropin treatment is highly individualized. Doses are carefully adjusted based on how your ovaries respond, which is closely monitored via pelvic ultrasounds and blood tests measuring estrogen levels. The medication is usually taken daily for about 7 to 12 days.

Special Considerations and Adjustments:

• Dose Capping: The maximum daily dose generally should not exceed 450 IU.
• Hepatic/Renal Impairment: While exact dosage adjustments for liver or kidney disease are not strictly defined due to the drug’s short-term use, caution and close metabolic monitoring are advised.
• Poor Responders vs. High Responders: Women with diminished ovarian reserve (low AMH levels) may require higher starting doses, while women with Polycystic Ovary Syndrome (PCOS) are started on very low doses to prevent overstimulation.

Clinical Efficacy and Research Results

Clinical data collected from global ART registries (2020-2026) continues to demonstrate that highly purified urofollitropin is highly effective for follicle stimulation, comparable to recombinant FSH forms.

• Ovulation Induction Success: In women treated for anovulation (who are otherwise healthy), ovulation is successfully induced in up to 70 to 80 percent of treatment cycles.
• Clinical Pregnancy Rates: For women undergoing IVF utilizing urofollitropin, clinical pregnancy rates are highly dependent on maternal age. Recent clinical averages show a live birth rate of approximately 35 to 45 percent per cycle for women under 35, gradually decreasing for women in their late 30s and 40s.
• Follicle Yield: In standard IVF protocols, urofollitropin successfully yields an average of 8 to 15 mature oocytes (eggs) per retrieval, providing a strong foundation for embryo creation.

Safety Profile and Side Effects

WARNING: OVARIAN HYPERSTIMULATION SYNDROME (OHSS) AND MULTIPLE BIRTHS

While there is no formal “Black Box Warning,” all gonadotropins carry severe warnings regarding OHSS, a potentially life-threatening condition where the ovaries become swollen and fluid leaks into the abdomen and chest. Furthermore, stimulating multiple eggs significantly increases the risk of multiple pregnancies (twins, triplets), which carry higher risks for both the mother and babies.

Common Side Effects (>10%)

• Headache
• Injection site reactions (redness, pain, or bruising at the injection site)
• Abdominal cramping, bloating, or mild pelvic pain (due to enlarging ovaries)
• Nausea
• Breast tenderness

Serious Adverse Events

• Ovarian Hyperstimulation Syndrome (OHSS): Symptoms include severe abdominal pain, rapid weight gain, vomiting, and shortness of breath.
• Ovarian Torsion: The enlarged ovaries can twist on their blood supply, requiring emergency surgery.
• Thromboembolism (VTE): Blood clots in the legs or lungs, often associated with severe OHSS.
• Ectopic Pregnancy: A pregnancy that develops outside the uterus (e.g., in the fallopian tubes).

Management Strategies

• OHSS Prevention: If ultrasound shows too many follicles developing, or if estrogen levels rise too high, your doctor will withhold the final “trigger shot” (hCG) to prevent OHSS. This is known as “coasting” or cycle cancellation.
• Pain Management: Mild bloating is normal, but sudden, sharp pain must be evaluated immediately to rule out ovarian torsion.

Connection to Stem Cell and Regenerative Medicine

In modern reproductive endocrinology, combining Biologic fertility drugs like urofollitropin with regenerative medicine is a groundbreaking area of research. Many older women, or those with Premature Ovarian Insufficiency (POI), suffer from “Poor Ovarian Response,” meaning their ovaries do not respond to urofollitropin injections. Currently, researchers and clinicians are exploring “Ovarian Rejuvenation” therapies. This involves injecting Platelet-Rich Plasma (PRP) or mesenchymal stem cells directly into the ovaries a few months before starting urofollitropin. Early clinical studies aim to see if these regenerative treatments can awaken dormant follicles, restore blood flow, and repair surrounding ovarian tissue, thereby making the ovaries responsive to urofollitropin once again.

Disclaimer: The research mentioned regarding “Ovarian Rejuvenation” using Platelet-Rich Plasma (PRP) or mesenchymal stem cells to restore responsiveness to urofollitropin is a significant and active area of clinical investigation. While these therapies are being offered in specialized centers, they remain exploratory and are not yet established as the universal standard of care or part of validated professional clinical protocols in 2026.

Patient Management and Practical Recommendations

Pre-treatment Tests

• Baseline Pelvic Ultrasound: A transvaginal ultrasound is required on Day 2 or 3 of your cycle to ensure there are no existing ovarian cysts before starting the medication.
• Ovarian Reserve Testing: Blood tests for AMH (Anti-Mullerian Hormone) and Day 3 FSH levels to predict how you will respond to the medication.
• General Health Screening: Routine baseline labs, thyroid testing, and a pregnancy test.

Precautions During Treatment

• Symptom Vigilance: Monitor your weight daily. Rapid weight gain (more than 2 to 3 pounds in a day), severe bloating, or decreased urination are early signs of OHSS and must be reported to your doctor immediately.
• Physical Activity Limitations: Because your ovaries will become enlarged and heavy, you must avoid high-impact exercises, heavy lifting, or vigorous sexual intercourse to prevent ovarian torsion.

Do’s and Don’ts

• DO rotate your injection sites daily (e.g., alternating sides of the lower abdomen) to prevent tissue irritation.
• DO take the injection at the exact same time every day to maintain steady hormone levels.
• DO store the medication exactly as directed by your pharmacist (some forms require refrigeration, others can be kept at room temperature away from light).
• DON’T mix different vials of medication unless explicitly instructed by your fertility nurse.
• DON’T ignore severe nausea, shortness of breath, or sharp pelvic pain.
• DON’T skip your monitoring appointments; ultrasounds and bloodwork are critical to keeping you safe and adjusting your dose.

Legal Disclaimer

The information provided in this guide is for educational and informational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician, gynecologist, reproductive endocrinologist, or other qualified healthcare provider with any questions you may have regarding a medical condition, fertility treatment, or medication. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.